Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera.

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2024-11-11 DOI:10.1038/s41541-024-01016-6

Kun Xu, Yaling An, Xueyuan Liu, Haitang Xie, Dedong Li, Ting Yang, Minrun Duan, Yuanzhuo Wang, Xin Zhao, Lianpai Dai, George F Gao

引用次数: 0

Abstract

We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

查看原文本刊更多论文

人和小鼠血清中和 SARS-CoV-2 KP.1、KP.1.1、KP.2 和 KP.3。

我们报告了 SARS-CoV-2 KP.1、KP.1.1、KP.2 和 KP.3 中和抗体滴度。对于经历过 BF.7/BA.5.2 突破性感染或接受过二价（delta/BA.5）疫苗强化的参与者，与 JN.1 相比，它们显示出更强的免疫逃避能力，尤其是 KP.1 和 KP.3。第二个 XBB 亚变体的突破性感染增强了中和反应。HK.3-JN.1 RBD-heterodimer能诱导小鼠对最近流行的SARS-CoV-2亚变体产生平衡而有效的中和反应，支持取代含有JN.1或其亚变体的COVID-19抗原。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.